General Information
|
|
Product
|
IFITM3 Peptide
|
Description
|
Antigenic Blocking Peptide Interferon-induced transmembrane protein 3
|
Verified Applications
|
Immunodepletion, Immunocompetition
|
Peptide Description
|
Synthetic peptide taken within amino acid region 1-50 on human Interferon-induced transmembrane protein 3.
|
Accession #
|
GenBank: AFF60350
|
Physical Properties
|
|
Quantity
|
250 µg
|
Volume
|
100 µl
|
Form
|
Antigenic Blocking Peptide
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
Protein
|
Uniprot #
|
Q01628
|
Overview
|
IFN-induced antiviral protein which disrupts intracellular cholesterol homeostasis. Inhibits the entry of viruses to the host cell cytoplasm by preventing viral fusion with cholesterol depleted endosomes. May inactivate new enveloped viruses which buds out of the infected cell, by letting them go out with a cholesterol depleted membrane. Active against multiple viruses, including influenza A virus, SARS coronavirus (SARS-CoV), Marburg virus (MARV) and Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV S protein-mediated viral entry and VSV G protein-mediated viral entry. Plays a critical role in the structural stability and function of vacuolar ATPase (v-ATPase). Establishes physical contact with the v-ATPase of endosomes which is critical for proper clathrin localization and is also required for the function of the v-ATPase to lower the pH in phagocytic endosomes thus establishing an antiviral state.
|
Molecular Function
|
Antiviral defense, Immunity, Innate immunity
|
Subcellular Location
|
Cell membrane; Single-pass type II membrane protein
Late endosome membrane; Single-pass type II membrane protein
Lysosome membrane; Single-pass type II membrane protein
|
Expression
|
Induced by IFN-alpha and IFNG/IFN-gamma.
|
Structure
|
Interacts with ATP6V0B and CD81. Interacts with SPP1; the interaction reduces OPN expression. Interacts with VAPA.
|
Alternative Nomenclature
|
1 8U antibody
Fragilis antibody
IFITM3 antibody
Interferon Induced Transmembrane Protein 3 antibody
Interferon inducible antibody
Interferon inducible protein 1 8U antibody
Interferon Inducible Protein 15 antibody
Interferon Inducible Protein Homolog antibody
IP15 antibody
|
|
|